Medicare would pay separately for newer outpatient cancer drugs
In committeeH.R. 8032Latest action
Sponsor: Neal P. Dunn · Representative · FL
AIDecoded by AI · checked against the recordRead the official text
Official title: FAIC Act
119th Congress
Topics: Health care
Introduced:
Read the official bill on Congress.govIn plain words
The plain-language version comes first. The official text is always the reference.
Medicare would pay separately for newer cancer drugs costing $350/day or more instead of folding them into one bundled payment.
50-second read · 5 questions answered below
What does this do?
This bill changes how Medicare pays for certain cancer drugs and biologics given in outpatient settings. If a cancer treatment was FDA-approved on or after January 1, 2008, and its estimated daily cost reaches or exceeds $350, Medicare must pay for it separately rather than bundling it into the overall visit payment. That $350 threshold would increase each year with inflation, and the separate payment would generally be based on the drug's average sales price.
Who does it affect?
This bill affects hospitals and other outpatient providers that give these cancer treatments. Medicare patients who receive costly newer cancer therapies are also affected.
Why does it matter?
Under the current bundled system, hospitals may not be fully covered for the cost of expensive newer drugs. If providers cannot cover those costs, some patients could lose access to these therapies.
What does it cost, and who pays?
- Medicare pays cancer drugs separately
- Based on average sales price
- Not bundled in single payment
AI-drafted summary. Check it against the official text before you act on it.
Read the official bill on Congress.govMake the call
Where does it stand?
- IntroducedMar 20, 2026
- House committeeYou are here · Mar 20, 2026
- House vote
- Senate
- The president's desk
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the president.
Latest action: — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.